Merck Cholesterol Pill

The FDA approved Merck's first-of-its-kind pill for high-risk cholesterol patients.

8

Articles

8

Sources

13%

Analysis & opinion

The reporting

A neutral summary of the key facts most outlets agree on, drawn from reporting across the political spectrum.

The FDA approved Merck’s Lipfendra, making it the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol. The pill is authorized for people with hypercholesterolemia whose artery-clogging cholesterol remains high despite statins, the standard drugs used to lower heart-attack risk. PCSK9 inhibitors block a protein that limits the liver’s removal of LDL from the blood, a treatment approach previously available only as injections. In trials cited by Merck, Lipfendra cut LDL by nearly 60%, comparable to injectable PCSK9 drugs.

Analysis & opinion

The arguments that emerged from this coverage — built only from the analysis and opinion pieces, never from straight reporting. Each dot is one article, placed by its outlet's bias — left to right. How to read our graphics →

The commentary is scattered.

weigh in — but each argues its own distinct claim, so no shared angle emerged. The other report the story straight.

Get tomorrow's edition

Every side, every morning — free in your inbox.

More of today's stories

all of today's stories →